Angel Matthew 4

4 · Tempest Therapeutics, Inc. · Filed Mar 25, 2026

AI-generated summary of this filing

Updated Mar 25, 2026

Tempest Therapeutics (TPST) 10% Owner Matthew Angel Buys 231,482 Shares

What Happened

Matthew Angel, reported as a 10% owner of Tempest Therapeutics (TPST), acquired 231,482 shares on March 24, 2026. The transaction was reported as a purchase (code P) at $2.16 per share, for a total reported value of $500,001. The filing indicates the purchase was an open market or private purchase.

Key Details

Transaction date and price: 2026-03-24, 231,482 shares at $2.16 each.
Total value: $500,001.
Shares owned after the transaction: not specified in the provided filing excerpt.
Footnote summaries:
- F1: The shares are held by Factor Bioscience Inc. The reporting person is CEO and chairman of Factor and disclaims beneficial ownership except for any proportionate pecuniary interest.
- F2: The filing reflects pro rata distributions of shares by Erigen LLC to its members after the reporting person's last Section 16 filing; that distribution was a change in form of ownership and did not require separate reporting.
Filing timeliness: Form 4 was filed on 2026-03-25 (one day after the transaction), i.e., timely reported.

Context

As a 10% owner and through an entity (Factor Bioscience), this acquisition may reflect institutional/entity-level ownership rather than a simple personal trade. The F1 disclosure indicates the reporting person’s ownership is via Factor and is limited to any pecuniary interest.
Purchases by insiders can be informative, but they do not by themselves indicate the insider's motive or guarantee future stock performance.

Form 4

Period: 2026-03-24

DirectorCEO and President10% Owner

Transactions

Purchase
Common Stock
[F1]
2026-03-24$2.16/sh+231,482$500,001→ 231,482 total(indirect: By Factor Bioscience Inc.)

Holdings

Footnotes (2)

[F1]The shares are held by Factor Bioscience Inc. ("Factor"). The Reporting Peron is the chief executive officer and chairman of the board of directors of Factor and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.
[F2]The shares reported herein give effect to the pro rata distributions of shares by Erigen LLC for no additional consideration to its members, subsequent to the Reporting Person's last Section 16 filing reporting ownership of the Issuer's Common Stock. As the distribution of such shares constituted only a change in the form the Reporting Person's ownership in such shares, the Reporting Person was not required to report the distribution pursuant to Section 16.

Signature

/s/ Matthew Angel|2026-03-25

1 file